262 related articles for article (PubMed ID: 27595409)
1. Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants.
Trikha R; Kowey PR
Cardiology; 2017; 136(2):115-124. PubMed ID: 27595409
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
[TBL] [Abstract][Full Text] [Related]
3. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
4. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
[TBL] [Abstract][Full Text] [Related]
5. The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Liu X; Huang M; Ye C; Zeng J; Zeng C; Ma J
Medicine (Baltimore); 2020 Jul; 99(27):e21025. PubMed ID: 32629725
[TBL] [Abstract][Full Text] [Related]
6. [Anticoagulation for patients with non-valvular atrial fibrillation].
Mizoguchi T; Yasaka M
Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
[TBL] [Abstract][Full Text] [Related]
7. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
8. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
[TBL] [Abstract][Full Text] [Related]
9. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
[TBL] [Abstract][Full Text] [Related]
12. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Orenes-Piñero E; Romiti GF; Romanazzi I; Bai Y; Carmo J; Proietti M; Marín F; Lip GYH
Am J Cardiol; 2018 Sep; 122(5):785-792. PubMed ID: 30049460
[TBL] [Abstract][Full Text] [Related]
13. Overview of the new oral anticoagulants: opportunities and challenges.
Yeh CH; Hogg K; Weitz JI
Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1056-65. PubMed ID: 25792448
[TBL] [Abstract][Full Text] [Related]
14. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
15. New oral anticoagulants for patients with nonvalvular atrial fibrillation.
Holden A; Azimi N; Forest CP
JAAPA; 2015 Nov; 28(11):28-34. PubMed ID: 26501575
[TBL] [Abstract][Full Text] [Related]
16. The new oral anticoagulants: Reasonable alternatives to warfarin.
Roca B; Roca M
Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation Therapy and NOACs in Heart Failure.
Thomas I; EncisoSilva J; Schlueter M; Greenberg B
Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
[TBL] [Abstract][Full Text] [Related]
18. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Morimoto T; Crawford B; Wada K; Ueda S
J Cardiol; 2015 Dec; 66(6):466-74. PubMed ID: 26162944
[TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Sjögren V; Byström B; Renlund H; Svensson PJ; Oldgren J; Norrving B; Själander A
PLoS One; 2017; 12(7):e0181000. PubMed ID: 28700711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
